Proactive investorsLogo Proactive Investors UK Website

Search field
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: HGN
News: Latest news
Web Site: Halcygen Pharmaceuticals Limited
Other Articles:

RSS - Subscribe to the News Today on Proactive UK ▼

Tuesday February 09, 07:53Mediterranean Oil & Gas doubles proven and probable reserves for Ombrina Mare to 40 mmbbls

The good news gave a welcome boost to the group's share price, sending the stock up nearly 15 percent in early trade.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Tuesday February 09, 11:07Randgold Resources remains focused on 1 million ounce production target

Speaking to assembled analysts in London, Randgold Resources CEO, Mark Bristow, told of a ‘great year' for his company, albeit also a challenging one, but one which would position it well for the years ahead

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Tuesday February 09, 01:53Chindex International reports increasing medical and healthcare revenues

Healthcare products and services group Chindex International (NASDAQ: CHDX) reported increasing revenues as it continued to expand its operations in the People’s Republic of China (PRC).

FULL ARTICLE ►
Halcygen Pharmaceuticals Limited

Halcygen Pharmaceuticals Limited

HalcyGen Pharmaceuticals Limited focuses to bring reformulated existing drugs to the market, known as SuperGenerics. The Company has two development programmes: SUBA-itraconazole and Minocycline. SUBA-itraconazole is a bioavailable formulation of itraconazole, a synthetic broad-spectrum anti-fungal agent. Minocycline is a member of the tetracycline antibiotic family. Minocycline is used to treat bacterial infections, including pneumonia and other respiratory tract infections, acne and infections of skin, genital, and urinary systems. It can also be used to eliminate bacteria from the nose and throat.
Friday, August 28, 2009

Halcygen files for registration of anti-fungal product, SUBA-Itraconazole

company news image

Developer of improved variants of existing proprietary pharmaceuticals known as super generics, HalcyGen Pharmaceuticals (ASX: HGN) has filed a registration of its anti-fungal product, known as SUBA-Itraconazole, in the EU.

Super generic drugs are reformulations of off-patent drugs and bridge the gap between mainline and pharmaceutical companies and high volume generics.  They can often enjoy patent protected positions and have higher margins.

SUBA-Itraconazole is a "value added formulation" of the anti-fungal drug Sporanox®. The anti-fungal target market is a worldwide annual $600 million market. SUBA-Itraconazole has significant benefits relative to Sporanox®.

Dr Roger Aston chief executive officer of HalcyGen said the company is working on appointing marketing and distribution partners for the EU.

Aston said discussions are underway with several pharmaceutical companies. When launched in the EU market, SUBA-Itraconazole will be competing in the European itraconazole market which is currently over US$120 million per year.”

He said SUBA-Itraconazole would be registed in the EU in 2010, following meeting with Sweden’s MPA and the UK’s medicines and healthcate products regulatory agency.

AddThis Feed Button
Register here to be notified of future Halcygen Pharmaceuticals Limited articles.

Investors interested in Halcygen Pharmaceuticals Limited recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.